Skip to search formSkip to main contentSkip to account menu

lexipafant

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Background:The management of acute pancreatitis (AP) is still based on speculative and unproven paradigms in many centers… 
Highly Cited
2001
Highly Cited
2001
BACKGROUND Platelet activating factor (PAF) is believed to amplify the activity of key mediators of the systemic inflammatory… 
Highly Cited
2000
Highly Cited
2000
ABSTRACT Platelet-activating factor (PAF) is a potent endogenous proinflammatory mediator implicated in the pathogenesis of… 
Highly Cited
1999
Highly Cited
1999
Endothelial barrier dysfunction is a critical link in the development of tissue injury and organ dysfunction, via upregulation… 
Highly Cited
1999
Highly Cited
1999
Objective: To assess the safety and tolerability of lexipafant in HIV-associated cognitive impairment. Background: Cognitive… 
Highly Cited
1997
Highly Cited
1997
Background Many patients with severe acute pancreatitis develop organ system failure during the first few days of illness, and… 
1996
1996
Acute pancreatitis is associated with the development of pulmonary dysfunction in a number of patients. The aim of this study was… 
1996
1996
Objective: To assess the anti-inflammatory action of lexipafant (BB-882), a platelet activating factor antagonist, in an animal… 
Highly Cited
1995
Highly Cited
1995
The aims of the study were to determine whether the platelet‐activating factor antagonist Lexipafant could alter the clinical…